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112 children per 100,000 have congenital permanent hearing loss, 90% of whom have sensorineural hearing loss1. 21
children per 100,000 will acquire hearing loss. Approximately 50% of children have moderate (30 - 50 dB), 25% severe
(50 - 70 dB) and 25% profound (more than 70 dB) hearing impairment2. These levels correspond to inability to hear a
whisper, ordinary conversation or a shout respectively.
Audiological status alone is a poor indicator of later academic achievements of the child with hearing impairment3.
Children with hearing loss and hearing aids fitted before 6 months of age, achieve language and social development
levels within the normal range4. Thus, a normal outcome is more likely following an early diagnosis.
In 1997, the median age at diagnosis of all hearing impairment in the United Kingdom was 20 months. with more severe
hearing loss being diagnosed earlier: severe hearing loss at median 11 months and profound hearing loss at median 9
months5. This demonstrates failure of early diagnoses of hearing loss.
The currently accepted standard test for hearing screening in Ireland is the health visitor distraction test,
described initially by Ewing and Ewing in 19446 and improved by McCormick7-9 in the 1980s. The basis of this test is
that a baby aged 6 to 7 months normally turns his head to locate the source of a sound. When sounds of different
frequencies are presented, the level of hearing loss can be ascertained. This test performs favourably when
appropriate training and support is given to testers10,11. In 1992, the distraction test reported 96% coverage and 88%
sensitivity for hearing losses over 50 dB over a 4 year period10. However, this test is operator dependent and, in
1997, a substantial decline in its success rate was reported12 following a management reorganisation. Following
identification and rectification of this problem, improvement in performance to previous levels was reported13. This
demonstrates the vulnerability and subjective bias of this test14.
At present, there is no mandated screening programme for hearing impairment in this country. Many paediatric units
have their own criteria for screening selected patients. Some base their indicators of high risk of sensorineural and
/ or conductive hearing loss in neonates, as published by the American Academy of Paediatrics in 1994 - See Table 1.15
This position statement also encourages the detection of hearing loss before 3 months of age and necessary
interventions to be instituted before 6 months of age. Unfortunately, targeted neonatal hearing screening misses an
estimated 50% of patients with congenital or early acquired neonatal hearing loss.
Current trends both in the United Kingdom and in the United States of America are to implement universal neonatal
hearing screening
Table 1 Indicators Associated With Sensorineural and/or Conductive Hearing Loss
For use with neonates (birth through age 28 days) when universal screening is not available
Family history of hereditary childhood sensorineural hearing loss
In utero infection, such as cytomegalovirus, rubella, syphilis, herpes simplex, or toxoplasmosis
Craniofacial anomalies, including those with morphologic abnormalities of the pinna and ear canal
Birth weight less than 1500 g (3.3 lb)
Hyperbilirubinemia at a serum level requiring exchange transfusion
Ototoxic medications, including but not limited to the aminoglycosides, used in multiple courses or in combination
with loop diuretics
Bacterial meningitis
Apgar scores of 0 to 4 at 1 min or 0 to 6 at 5 min
Mechanical ventilation lasting 5 days or longer
Stigmata or other findings associated with a syndrome known to include a
sensorineural and/or conductive hearing loss
Adapted from American Academy of Pediatrics, Joint Committee on Infant Hearing: Joint Committee on Infant Hearing 1994
Position Statement. Pediatrics 95:152, 1995.
programmes. Controlled clinical trials have shown the effectiveness, efficiency and reliability of universal neonatal
hearing screening16. New methods developed for neonatal hearing screening include Otoacoustic Emission Tests, Auditory
Brain Stem Response Testing and Portable Auditory Response Cradles.
Otoacoustic Emission Tests (OAEs)
Otoacoustic emissions, first described in 1978 by Kemp,17 are thought to originate from the active biomechanics or
cochlear echoes of the cochlear sensory mechanism at a preneural level14 . A small soft-tipped probe is placed in the
child’s external ear canal and this records the presence or absence of acoustic echoes, generated by the cochlea in
response to acoustic stimulation. This test is inexpensive, non-invasive, sensitive and is conducted in less than one
minute. It does not detect rare retrocochlear disease.
Auditory Brain Stem Response Testing
This is an auditory evoked electrophysiologic response that correlates well with hearing. Electrical activity in the
brain is measured by scalp electrodes. Hearing can be screened at any level. Retrocochlear function is tested. The
test takes approximately 20 to 30 minutes.
Portable Auditory Response Cradles
Transducers are positioned around the infant to detect behavioural reaction to sounds. All decibels of sound can be
examined. Reports conflict on the efficacy and reliability of this screening method.18-19 This may be due to
inadequately refined early versions of the equipment.
One of the main advantages of the OAE method is that it is comparatively inexpensive. In 2001, Vohr20 compared the OAE
and ABR methods and concluded that otoacoustic emission testing is more cost-effective per patient tested and is
quicker to perform, thus decreasing the time spent by the audiologist per patient. But OAEs are more likely to result
in a higher referral rate for further hearing testing, sometimes exceeding the maximum limit of 4% recommended by the
AAP.
21
The European Consensus Development Conference on Neonatal Hearing Screening in Milan, Italy in 1998 concluded that
targeted neonatal hearing screening in parallel with the health visitor distraction test is more expensive and less
effective than universal neonatal hearing screening.22 In this era of medical accountability and audit, the use of the
HVDT and targeted neonatal hearing screening is not the best practice of modern medicine. Perhaps the time has come
for Irish institutions to answer the call for universal neonatal hearing screening.
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